SCM
CLDX icon

Soleus Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Soleus Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-13,600
Closed -$461K – 99
2023
Q2 		$461K Buy
+13,600
New +$458K 0.05% 96
2022
Q2 		– Sell
-69,000
Closed -$2.35M – 73
2022
Q1 		$2.35M Buy
+69,000
New +$2.21M 0.3% 52

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Soleus Capital Management's CLDX Position: Q3 2023 in Review

Soleus Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2023, closing a stake of 13,600 shares — an estimated $461K sold.

Soleus Capital Management first reported a position in CLDX in Q1 2022 and held it in 2 quarters. The position peaked at $2.35M in Q1 2022. 144 funds tracked by Wall St. Rank hold CLDX as of Q3 2023.

  • Soleus Capital Management reported no remaining Celldex Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 13,600 Celldex Therapeutics shares in Q3 2023, an estimated $461K.
  • Soleus Capital Management first reported a position in Celldex Therapeutics in Q1 2022 and held it in 2 quarters.
  • Soleus Capital Management's Celldex Therapeutics position peaked at $2.35M in Q1 2022.
  • 144 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.